FEMA No. 3565 en es it fr

FEMA No. 3565 Brand names, FEMA No. 3565 Analogs

FEMA No. 3565 Brand Names Mixture

  • No information avaliable

FEMA No. 3565 Chemical_Formula

C4H7N1O4

FEMA No. 3565 RX_link

No information avaliable

FEMA No. 3565 fda sheet

FEMA No. 3565 msds (material safety sheet)

http://domino.solutia.com/solutia/smsdslib.nsf/0/561ad1a8b4bae67c8625636000511152/$FILE/English.pdf

FEMA No. 3565 Synthesis Reference

No information avaliable

FEMA No. 3565 Molecular Weight

133.104 g/mol

FEMA No. 3565 Melting Point

230 oC

FEMA No. 3565 H2O Solubility

4.5 g/l

FEMA No. 3565 State

Solid

FEMA No. 3565 LogP

-0.67 +/- 0.36

FEMA No. 3565 Dosage Forms

Capsules and powder

FEMA No. 3565 Indication

There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

FEMA No. 3565 Pharmacology

L-aspartate is considered a non-essential amino acid, meaning that, under normal physiological conditions, sufficient amounts of the amino acid are synthesized in the body to meet the body's requirements. L-aspartate is formed by the transamination of the Krebs cycle intermediate oxaloacetate. The amino acid serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. L-aspartate is a glycogenic amino acid, and it can also promote energy production via its metabolism in the Krebs cycle. These latter activities were the rationale for the claim that supplemental aspartate has an anti-fatigue effect on skeletal muscle, a claim that was never confirmed.

FEMA No. 3565 Absorption

Absorbed from the small intestine by an active transport process

FEMA No. 3565 side effects and Toxicity

Mild gastrointestinal side effects including diarrhea. LD50 (rat) > 5,000 mg/kg.

FEMA No. 3565 Patient Information

No information avaliable

FEMA No. 3565 Organisms Affected

Humans and other mammals